Amgen to make oncology presentations

Amgen has announced that it is to make a number of presentations at the annual meeting of the European Conference on Clinical Oncology (ECCO) being held this week in Barcelona.

The firm will exhibit its supportive care portfolio and therapeutic agents at the seminar, including clinical trial data relating to Araenesp (darbepoetin alfa), Neulasta (pegfilgrastim), Vectibix (panitumumab) and investigational compound AMG 386.

Amgen will exhibit evaluations of the association between safety outcomes in oncology with haemoglobin levels in patients with chemotherapy-induced anaemia, while also presenting treatment analysis of patients with breast cancer, metastatic colorectal cancer and advanced solid tumours.

Roger M Perlmutter, executive vice-president of research and development at Amgen, said: “The breadth and diversity of the data we’re presenting at ECCO this year reflects our commitment to exploring multiple pathways and serving the individual treatment needs of patients.”

He added that the company is dedicated to improving the science and treatment of patients in the field of oncology.

Earlier this month, Amgen presented the results of a phase III clinical study of Aranesp to the World Conference on Lung Cancer in Seoul.

The compound showed no negative impact on survival, with the study building on the ongoing pharmacovigilance initiative relating to the long-term use of the compound in anaemia patients being treated with concomitant chemotherapy.